Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials

Taha Sen; Viktor Rotbain Curovic; Niels Jongs; Gozewijn D Laverman; Adriaan Kooy; Frederik Persson; Peter Rossing; Hiddo J L Heerspink

doi:10.1111/dom.15109

Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials

Diabetes Obes Metab. 2023 Aug;25(8):2413-2418. doi: 10.1111/dom.15109. Epub 2023 May 11.

Authors

Taha Sen¹, Viktor Rotbain Curovic², Niels Jongs¹, Gozewijn D Laverman³, Adriaan Kooy⁴, Frederik Persson², Peter Rossing², Hiddo J L Heerspink^{1

5}

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
² Steno Diabetes Centre Copenhagen, Herlev, Denmark.
³ ZiekenhuisGroep Twente, Almelo, The Netherlands.
⁴ Bethesda Diabetes Research Centre, Hoogeveen, The Netherlands.
⁵ The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.

PMID: 37166080
DOI: 10.1111/dom.15109

No abstract available

Keywords: ARB; DPP-4 inhibitor; JAK-STAT inhibitor; SGLT2 inhibitor; baricitinib; empagliflozin; inflammation; inflammatory markers; linagliptin; telmisartan.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Albuminuria / drug therapy
Benzhydryl Compounds / pharmacology
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Dipeptidyl-Peptidase IV Inhibitors*
Humans
Hypoglycemic Agents / pharmacology
Inflammation / drug therapy
Linagliptin / pharmacology

Substances

Linagliptin
Hypoglycemic Agents
Benzhydryl Compounds
Dipeptidyl-Peptidase IV Inhibitors